{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":12,"n_cols":3,"rows_kept":12,"merged":[[1,0,2,0]],"flags":["formulas_cached_only"]}
["Supp Table 5. Summary of Adverse Events in Patients With Wild-Type KRAS Exon 2 and Mutant Other RAS Exons "]
[null,"Panitumumab Plus BSC","BSC alone"]
[null,"(n=26)","(n=28)"]
["Patients with any adverse event, n (%)","25 (96.2)","19 (67.9)"]
["Worst grade of 3","7 (26.9)","4 (14.3)"]
["Worst grade of 4","4 (15.4)","1 (3.6)"]
["Worst grade of 5","1 (3.8)","2 (7.1)"]
["Any serious","9 (34.6)","6 (21.4)"]
["Leading to permanent discontinuation of any study drug","5 (19.2)","−"]
["Not serious","3 (11.5)","−"]
["Serious","2 (7.7)","−"]
["BSC, best supportive care."]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}